Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Gains from Sales and Divestitures: 2015-2024

Historic Gains from Sales and Divestitures for Seres Therapeutics (MCRB) over the last 9 years, with Dec 2024 value amounting to $2.2 million.

  • Seres Therapeutics' Gains from Sales and Divestitures fell 96.29% to $52,160 in Q3 2025 from the same period last year, while for Sep 2025 it was $52,160, marking a year-over-year decrease of 96.29%. This contributed to the annual value of $2.2 million for FY2024, which is 44.01% up from last year.
  • Per Seres Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $2.2 million for FY2024, which was up 44.01% from $1.5 million recorded in FY2023.
  • In the past 5 years, Seres Therapeutics' Gains from Sales and Divestitures registered a high of $2.2 million during FY2024, and its lowest value of $125,000 during FY2020.
  • Over the past 3 years, Seres Therapeutics' median Gains from Sales and Divestitures value was $1.5 million (recorded in 2023), while the average stood at $1.3 million.
  • Data for Seres Therapeutics' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 439.89% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Seres Therapeutics' Gains from Sales and Divestitures stood at $125,000 in 2020, then reached $282,401 in 2022, then spiked by 439.89% to $1.5 million in 2023, then soared by 44.01% to $2.2 million in 2024.